Eli Lilly’s Metabolic Medicine Takes the Lead in the Race to Develop an Oral GLP-1 Drug
MedCity News
APRIL 17, 2025
The first Phase 3 results for Eli Lillys daily pill orforglipron show statistically significant reductions in blood sugar and body weight in patients with type 2 diabetes. The post Eli Lillys Metabolic Medicine Takes the Lead in the Race to Develop an Oral GLP-1 Drug appeared first on MedCity News.
Let's personalize your content